Novartis recall
This article was originally published in The Tan Sheet
Executive Summary
Novartis is voluntarily recalling five lots of GenTeal eye gel and two lots of GenTeal gel drops, the firm announces Nov. 16. The recall is a result of concerns regarding product sterility in both products. Novartis found the presence of mold in "a small number of samples" of the eye gel which may cause infection in susceptible people, particularly those with compromised immune systems, the company states. The sterility of the gel drops also was contested due to a risk of potential contamination. Consumers who may have purchased the products should contact Novartis, the company states...You may also be interested in...
Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6
University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: